Accounting for bias due to a non-ignorable tracing mechanism in a retrospective breast cancer cohort study

2010 ◽  
Vol 30 (4) ◽  
pp. 324-334 ◽  
Author(s):  
Andrew C. Titman ◽  
Gillian A. Lancaster ◽  
Katie Carmichael ◽  
Diane Scutt
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Breast Cancer Cohort

scholarly journals 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

BMJ ◽  
2005 ◽  
Vol 330 (7485) ◽  
pp. 217 ◽  
Author(s):  
Gianni Bonadonna ◽  
Angela Moliterni ◽  
Milvia Zambetti ◽  
Maria Grazia Daidone ◽  
Silvana Pilotti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Operable Breast Cancer ◽  
Breast Cancer Cohort

scholarly journals Dietary changes in the first 3 years after breast cancer diagnosis: a prospective Chinese breast cancer cohort study

2018 ◽  
Vol Volume 10 ◽  
pp. 4073-4084 ◽  
Author(s):  
Yuan-Yuan Lei ◽  
Suzanne C. Ho ◽  
Ashley Cheng ◽  
Carol Kwok ◽  
Ka Li Cheung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Dietary Changes ◽  
Breast Cancer Cohort

scholarly journals Impact of surgery associated with radiotherapy on the prognosis of breast cancer – Guinea Breast Cancer Cohort Study

2021 ◽  
Author(s):  
Bangaly Traore ◽  
Mamady Keita ◽  
Abdoulaye Toure ◽  
Ibrahima Camara ◽  
Assiatou Barry ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Breast Cancer Cohort

scholarly journals Healthy Women's Motivators and Barriers to Participation in a Breast Cancer Cohort Study: A Qualitative Study

2009 ◽  
Vol 19 (7) ◽  
pp. 484-493 ◽  
Author(s):  
Pamela S. Sinicrope ◽  
Christi A. Patten ◽  
Sarah M. Bonnema ◽  
Julka R. Almquist ◽  
Christina M. Smith ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Qualitative Study ◽  
Barriers To Participation ◽  
Breast Cancer Cohort

Abstract A55: A prospective geriatric breast cancer cohort study to define unique features and outcomes in older breast cancer patients

2018 ◽  
Author(s):  
Anne M. Noonan ◽  
Janine A. Overcash ◽  
Anupama Suresh ◽  
Laura K. Flora ◽  
Julie Stephens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Breast Cancer Cohort

scholarly journals Incidence of Comorbidities in Women with Breast Cancer Treated with Tamoxifen or an Aromatase Inhibitor: An Australian Population-Based Cohort Study

2018 ◽  
Vol 8 (1) ◽  
pp. 16-24 ◽  
Author(s):  
Huah Shin Ng ◽  
Bogda Koczwara ◽  
David Roder ◽  
Theo Niyonsenga ◽  
Agnes Vitry
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Aromatase Inhibitor ◽  
Endocrine Therapy ◽  
Aromatase Inhibitors ◽  
Cancer Survival ◽  
Cox Regression ◽  
Cancer Control ◽  
Control Groups ◽  
Breast Cancer Cohort

Background The development of comorbidities has become increasingly relevant with longer-term cancer survival. Objective To assess the pattern of comorbidities among Australian women with breast cancer treated with tamoxifen or an aromatase inhibitor. Design Retrospective cohort study using Pharmaceutical Benefits Scheme (PBS) data (10% sample) from January 2003 to December 2014. Dispensing claims data were used to identify comorbidities and classified with the Rx-Risk-V model. The breast cancer cohort had tamoxifen or an aromatase inhibitor dispensed between 2004 and 2011 with no switching between types of endocrine therapy. Comparisons were made between the breast cancer cohort and specific control groups (age- and sex-matched at 1:10 ratio without any dispensing of anti-neoplastic agents during the study period) for the development of five individual comorbidities over time using Cox regression models. Results Women treated with tamoxifen had a higher incidence of cardiovascular conditions, diabetes, and pain or pain-inflammation, but a lower incidence of hyperlipidaemia compared with non-cancer control groups, as indicated by PBS data. Women treated with aromatase inhibitors were more likely to develop cardiovascular conditions, osteoporosis, and pain or pain-inflammation compared with non-cancer control groups. The risks of hyperlipidaemia and osteoporosis were significantly lower among tamoxifen users compared with aromatase inhibitor users. Conclusions Women with hormone-dependent breast cancer treated with an endocrine therapy had a higher risk of developing specified comorbid conditions than women without cancer, with different comorbidity profiles for those on tamoxifen versus aromatase inhibitors. Further research into the causes and mechanism of development and management of comorbidities after cancer is needed.

Sign in / Sign up

Export Citation Format

Share Document